MyMD Supera-CBD preclinical study shows rapid pain relief; Japanese patent granted

Q/C TECHNOLOGIES, INC.

Supera-CBD reduced acute inflammatory heat pain within 60 minutes; relief lasted up to five hours; traditional CBD had no effect.
Study at major academic center suggests Supera-CBD targets TRPV1 channels, potentially fewer side effects than opioids.
DEA determined Supera-CBD is not a controlled substance under the CSA; no scheduling required during development.
Japanese Patent No. 7293561 B2 issued for Supera-CBD as new molecular entity; company now holds 23 issued patents worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.